Clinical safety and possible efficacy of tirofiban in combination with intravenous thrombolysis by recombinant tissue plasminogen activator for early treatment of capsular warning syndrome (CWS)

• DOI: 10.3389/fnins.2022.1026127
• Publication Date: 2022-11-16T05:13:59Z
• Authors: Yunzhu Liu; Shiyong Li; Dongdong Hao; Zhongping Zhang; Yongxin Yi; Jiayang Fang; Weizhi Lin; Min Zhang
• Keywords: Tirofiban; Stroke

The purpose of this study was to assess the efficacy and safety combination tirofiban with intravenous thrombolysis (IVT) in treating patients capsular warning syndrome (CWS) who failed respond treatment alone. Tirofiban approved for CWS fluctuating symptoms or no substantial improvement after within 24 h our hospital from October 2019 June 2021. Patients were evaluated National Institutes Health Stroke Scale (NIHSS) at admission, 72 post-thrombolysis, 1-week, 3-months modified Rankin Scales (MRS) score. A total 12 received eight control a history cohort. Among patients, 13 smoked more than one pack cigarettes day, 17 had hypertension, hypercholesterolemia, 7 diabetes, 1 cerebral infarction, 2 atrial fibrillation, mild big vascular stenosis, lesions perforating branch by imaging, 19 acute infarction. In both groups, NIHSS scores significantly reduced 1-week onset compared before (P < 0.001). Before thrombolysis, there differences between group = 0.970, P 0.384, respectively). group, however, showed remarkably lower 3-month MRS 0.012, 0.003, Our revealed that did not increase risk hemorrhage favorable clinical as remedial poor prognosis therefore indicating great potential broader use.